Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06909773 | NOT YET RECRUITING | Cardiovascular Diseases

The Prevalence, Disease Burden and Prognosis of COPD in Patients With Cardiovascular Diseases
Sponsor:

AstraZeneca

Brief Summary:

This is a multi-center, prospective, and interventional study conducted in 3 types of cardiovascular diseases (CVD) subjects , including 3 cohorts which are patients with newly or previously diagnosed coronary heart disease ( CHD), atrial fibrillation ( AF) and chronic heart failure (CHF).

Condition or disease

Cardiovascular Diseases

Intervention/treatment

Guideline education and implementation intervention

Phase

NA

Detailed Description:

The mainly purpose of this study is describe the prevalence of COPD of the subjects with 3 types of CVD who are aged 40 years or older, and also observe the effect of cardiopulmonary co management on the short term prognosis of subjects with CVD and COPD. This study will enroll approximately 3,000 subjects, with approximately 1,000 subjects in each cohort.

Study Type : INTERVENTIONAL
Estimated Enrollment : 3000 participants
Masking : NONE
Primary Purpose : DIAGNOSTIC
Official Title : The Prevalence, Disease Burden and Prognosis of COPD in Patients With Cardiovascular Diseases -A Multi-center, Prospective, Interventional Study (PRECEDE)
Actual Study Start Date : 2025-05-31
Estimated Primary Completion Date : 2026-02-28
Estimated Study Completion Date : 2026-02-28

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 40 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • 1. Give signed written informed consent to participate.
  • 2. At least 40 years of age at baseline visit.
  • 3. Previous or newly diagnosed by at least one of the 3 types of CVD which are,
  • * Coronary heart disease ( CHD )
  • * Atrial fibrillation (AF )
  • * Chronic heart failure ( CHF )
  • 4. Subjects have no absolute contraindications to spirometry testing.
  • 5. Subjects have the cognitive ability to conduct questionnaires after e valuated by investigators.
Exclusion Criteria
  • 1. Significant diseases or conditions, which, in the opinion of the investigator, may put the subject at risk because of participation in the study or may influence either the results of the study or the subject's ability to participate in the study.
  • 2. Women who are pregnant or lactating or are planning to become pregnant, or women of childbearing potential who are not using an acceptable method of contraception.
  • 3. Subjects who are not able to provide written informed consent.
  • 4. Treatment with investigational study drug or device in another clinical study within the last 30 days or five half lives prior to baseline visit , whichever is longer.
The Prevalence, Disease Burden and Prognosis of COPD in Patients With Cardiovascular Diseases

Location Details

NCT06909773

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

No Location Found